H Tilly

2.8k citations
45 papers · 2.1k · 1 hit paper · h-index 16

Impact in

Papers in

H Tilly

44 papers receiving 2.0k citations

H Tilly's Hit Papers

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. 1998 · 753 citations
7530+9+18Years since publication250500750

Peers

H Tilly
Comparison fields: 5 of 73
  • Pathology and Forensic Medicine 1.2k
  • Genetics 578
  • Hematology 431
  • Oncology 687
  • Neurology 291
Replace Delvyn C. Case with:
Delvyn C. Case United States
R. E. Marcus United Kingdom
C Jacquillat France
Caterina Stelitano Italy
Mars B. van ’t Veer Netherlands
Michael Fridrik Austria
Margaret Macro France
Ana Balanzategui Spain
Isabelle Moullet France
DD Weisenburger United States
H Tilly relative to Delvyn C. Case United States Delvyn C. Case's profile →
Citations per field
00.5×
Delvyn C. Case · 1×
Citations per year

Countries citing papers authored by H Tilly

Since Specialization
Citations

This map shows the geographic impact of H Tilly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H Tilly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H Tilly more than expected).

Fields of papers citing papers by H Tilly

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H Tilly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H Tilly. The network helps show where H Tilly may publish in the future.

Co-authors

The 25 scholars most cited alongside H Tilly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H Tilly Line = papers co-authored together H Tilly links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Hit paper breakdown →
1998753
2 1989221
3 1992186
4 1997169
5 1993139
6 1996129
7 199281
8 200260
9 200056
10 199751
11 199146
12 199426
13 200519
14 199319
15 200917
16
Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1.
199117
17 202114
18 199911
19 19849
20 20078

About H Tilly

H Tilly is a scholar working on Pathology and Forensic Medicine, Hematology, Genetics, Molecular Biology and Public Health, Environmental and Occupational Health, having authored 45 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (11 papers), Acute Myeloid Leukemia Research (9 papers), Acute Lymphoblastic Leukemia research (7 papers), Retinoids in leukemia and cellular processes (4 papers), Hematopoietic Stem Cell Transplantation (3 papers), Glycosylation and Glycoproteins Research (2 papers) and Antifungal resistance and susceptibility (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.2k citations), Genetics (578 citations), Hematology (431 citations), Oncology (687 citations) and Neurology (291 citations). H Tilly has collaborated with scholars based in France, Belgium and Denmark. Frequent co-authors include Corinne Haïoun, F Reyes, John Radford, Renaud Capdeville, Peter Johnson, Michaela Feuring Buske, Volker Diehl, Andreas Engert, Nicolas Ketterer and Dengyan Ma. Their work appears in journals such as Journal of Clinical Oncology, Blood, Leukemia, Annals of Oncology and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact